Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1
Phase 3
Completed
- Conditions
- Heroin DependenceSubstance-Related Disorders
- Registration Number
- NCT00015171
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Brief Summary
The purpose of this study is the use of buprenorphine/naloxone in treatment of opioid dependence.
- Detailed Description
The objective of this study is to determine the safety and efficacy of a buprenorphine/naloxone combination tablet for opiate dependence treatment.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
DSM-IV diagnosis of current opiate dependence males and non-pregnant, non-nursing female 18-59 yrs of age
Exclusion Criteria
Any significant medical condition AST or ALT levels greater than 3x's the upper limit of normal level Current Axis I diagnosis other than opiate, caffeine or nicotine dependence
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Craving Drug use Retention Opioid withdrawal Subjective rating
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
New York MDRU
🇺🇸New York, New York, United States